The San Francisco-based company says the updates will accelerate radiology workflows by removing administrative burdens and freeing up radiologists to spend more time reviewing imaging exams instead. 

The technology is said to be twice as accurate at predicting five-year cancer risk compared to current risk assessment methods.

Experts are hopeful their device can address some of the shortcomings of currently used shielding methods. 

The method targets cancer stem cells, which are highly tumorigenic and known to play a significant role in relapse, cancer spread and treatment resistance.

Considering the often-aggressive nature of interval breast cancer, the findings could represent a significant step toward improving patient outcomes, authors of a new research paper suggest.

The American College of Radiology requested the update in June, with the changes now taking effect this month. 

“The results of our study deserve notice by other states considering similar legislation," says lead author Amy K. Patel, MD, chair of the ACR Advocacy Network. 

One of the country's largest operators of breast imaging centers is teaming with one of its biggest hospital systems to bolster services in 3 markets.